Souhaitez-vous accéder aux communiqués récents ?

Shire granted EU marketing authorization for ADYNOVI® [Antihemophilic Factor (Recombinant), PEGylated] for adults and adolescents with Hemophilia A Marketing Authorization will enable patient...

        Shire Announces Business Update at 36th Annual J.P. Morgan Healthcare Conference Projects continued strong growth as the global leader in rare diseases, led by the immunology...

Shire to present at the 36th Annual J.P. Morgan Healthcare Conference Cambridge, MA - January 4, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) announces that Flemming Ornskov, M.D., M.P.H., Chief...

       Shire Receives FDA Breakthrough Therapy Designation for Maribavir, an Investigational Treatment for Cytomegalovirus (CMV) Infection in Transplant Patients Cambridge,...

Xiidra®* (Lifitegrast Ophthalmic Solution 5%) Approved by Health Canada To Treat the Signs and Symptoms of Dry Eye Disease Canada approval represents Shire's first international market...

Total Voting Rights January 2, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company"), in accordance with 5.6.1R of the Financial Conduct Authority's (the "FCA") Disclosure Guidance and...

Director Declaration Dublin, Ireland - January 2, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") announces that Dominic Blakemore, Non-Executive Director of the Company, was appointed...

Shire files for FDA approval of a new plasma manufacturing facility in Covington, Georgia to support growing Immunology franchise Dublin, Ireland - December 27, 2017 - Shire plc (LSE: SHP,...

Director/PDMR Shareholding December 20, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) Notification of transactions by persons discharging managerial responsibilities 1. Details of the person...

SHIRE RECEIVES FDA CLEARANCE FOR MYPKFIT(TM) FOR ADVATE® [ANTIHEMOPHILIC FACTOR (RECOMBINANT)] TO HELP PERSONALIZE CARE FOR HEMOPHILIA A First and only FDA-cleared PK dosing software to support...